Short answer
CATALYST PHARMACEUTICALS, INC. (CPRX) filed an 8-K current report with the SEC on June 30, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Topline Phase 1 AGAMREE results announced on June 30, 2026.
CATALYST PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Topline Phase 1 AGAMREE results announced on June 30, 2026
- Vamorolone study advances AGAMREE development beyond existing indication
- Exhibit 99.1 contains study findings and potential investor-relevant safety or efficacy details
Item EX-99.1 · Exhibit EX-99.1
- Phase 1 topline data support vamorolone’s balanced profile: cortisol suppression and anti-inflammatory activity without significant immunosuppression at clinical doses
- Part A: 24 healthy adults showed comparable cortisol suppression versus 0.9 mg/kg deflazacort after 300 mg vamorolone
- Vamorolone produced less pronounced immunosuppressive biomarker effects than deflazacort, supporting switching and current DMD dosing
- Part B: 36 volunteers showed no relevant immunosuppression at 9 or 27 mg/kg/day; effects emerged only at 40 mg/kg/day
- Results could expand vamorolone’s lifecycle potential across chronic inflammatory rare diseases, though further development and commercialization remain uncertain
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CATALYST PHARMACEUTICALS, INC. 8-K filings
Get the next CPRX 8-K as it lands
Follow CPRX for push alerts, or ask the research agent what this filing means.